VetMedLokivetmab vs oclacitinib in dogs with atopic dermatitis: does one control itch and lesions better? — MAYBE (weak evidence)
In dogs with atopic dermatitis, does lokivetmab vs oclacitinib differ in itch and lesion control over 1–3 months?
Shelf #622 · gate-verified and displayed under the developer's blinded-trial rule
MAYBE (weak evidence): Only one record directly compares lokivetmab with oclacitinib in dogs with atopic dermatitis, and it is a single small research-colony study. In Marsella 2020 (PMID: 32301565; blinded, randomized, controlled study in 19 atopic beagle dogs challenged with allergen twice weekly and randomised to oclacitinib, ciclosporin, lokivetmab, prednisone or no treatment for four weeks), lesion scores (CADESI-03) in the first two weeks were significantly lower than controls with prednisone (P = 0.019) and with oclacitinib (P = 0.015), lokivetmab prevented flares, and — in the record's own words — due to variability no significant differences in pruritus were observed among groups; the area under the curve for hydration over time was higher for lokivetmab (P = 0.014) and for oclacitinib (P = 0.04) than for controls, and transepidermal water loss increased with time in controls but not in the oclacitinib and lokivetmab groups. The record reports no direct lokivetmab-versus-oclacitinib statistical comparison, so none of these findings shows one drug beating the other. A later knowledge summary (Cheung 2022, PMID: 42007020) critically appraised this one randomised trial and one before-and-after lokivetmab study and concluded there is insufficient quality of evidence to answer whether lokivetmab is more effective than oclacitinib, with further comparative study required. Design class (a) on design — randomisation and blinding are established by the carded Marsella 2020 record answering this shelf's own comparison in dogs with atopic dermatitis — but the stamp stays at MAYBE (weak evidence) because that record is one study of 19 colony beagles split across five groups, in an allergen-challenge model over four weeks only, whereas the shelf question spans 1–3 months in ordinary pet dogs. Scope limits: nothing here compares the drugs in client-owned dogs, beyond four weeks, or on safety; the neighbouring lokivetmab-versus-ciclosporin trial and the oclacitinib placebo trial home on Shelves #273 and #270 and are cross-pointed in the synthesis card, not re-carded. Drafted Nov 10, 2026 (VetMed build, topic #622); all figures from the abstracts fetched and verified at drafting.
Marsella 2020: in 19 allergen-challenged atopic beagles randomised across five groups, oclacitinib lowered lesion scores vs no treatment in the first 2 weeks and lokivetmab prevented flares, but no significant pruritus differences were found among groups and no direct lokivetmab-vs-oclacitinib comparison was reported
Blinded, randomized, controlled study in a research colony (record's own wording; publication types: Comparative Study, Journal Article, Randomized Controlled Trial, Veterinary)
Who: Dogs: 19 atopic beagle dogs in a research colony (not client-owned pet dogs), challenged with allergen twice weekly and randomized to oclacitinib, ciclosporin, lokivetmab, prednisone or no treatment for four weeks, in a controlled, blinded study. Dermatitis (Canine Atopic Dermatitis Extent and Severity Index, 3rd iteration — CADESI-03) and pruritus were assessed at baseline and after each challenge; transepidermal water loss (TEWL) and hydration were measured at baseline, Day 14 and Day 28 (pinnae, axilla, groin), and area under the curve (AUC) was calculated for CADESI-03, pruritus, TEWL and hydration.
Result: For CADESI-03, restricted maximum-likelihood ANOVA showed an effect of time and a group × time interaction (P = 0.0169); comparing the AUC of the first two weeks with the last two weeks, in the first two weeks prednisone and oclacitinib were significantly lower than controls (P = 0.019 and P = 0.015, respectively), and lokivetmab prevented flares. Due to variability, no significant differences in pruritus were observed among groups (the treatment made no difference). TEWL increased with time in controls (P = 0.0237) and in the ciclosporin group (P = 0.04, axilla, Day 28 versus Day 0) but not in the oclacitinib and lokivetmab groups; CADESI-03 correlated with TEWL (P = 0.0043) and pruritus (P = 0.0283); hydration did not correlate with any parameter, hydration decreased in controls and the prednisone group, and the AUC for hydration over time was higher for lokivetmab (P = 0.014) and oclacitinib (P = 0.04) than for controls. The authors conclude that lokivetmab prevented flares when given before challenge and that oclacitinib and lokivetmab have some positive effects on skin barrier parameters. The record reports each drug against the no-treatment control; it does not report a lokivetmab-versus-oclacitinib statistical test.
Watch out: VERY SMALL GROUPS: 19 dogs were split across five arms, so each treatment group holds only a handful of dogs and the study can miss real differences — its pruritus result is a non-finding in an underpowered comparison, not proof the drugs are equal. COLONY MODEL: research beagles challenged with allergen twice weekly are not client-owned pet dogs with naturally occurring atopic dermatitis, and the lokivetmab finding is framed as flare prevention when the drug was given before challenge. SHORT: four weeks of treatment, at the bottom of this shelf's 1–3 month window. The record does not state drug doses in its abstract, and it reports no safety comparison.
Marsella R, Ahrens K, Wilkes R, Trujillo A, Dorr M. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs. Vet Dermatol. 2020;31(4):284-e69. PMID: 32301565. Registry ID: none in the record. MeSH: Animals · Area Under Curve · Dermatitis, Atopic/drug therapy/veterinary* · Dermatologic Agents/classification/therapeutic use* · Dog Diseases/drug therapy* · Dogs · Female · Male · Prospective Studies · Pruritus/drug therapy/veterinary*
Synthesis: one small blinded colony trial is the whole direct evidence base, and the independent knowledge summary judged it insufficient to say whether lokivetmab beats oclacitinib — MAYBE (weak evidence)
Synthesis
Who: Synthesis of the card above (Marsella 2020, 19 research-colony atopic beagles) and of the review and neighbouring-shelf records documented in the result, which were fetched at drafting and deliberately not carded as claim-carriers.
Result: (1) Direct head-to-head: Marsella 2020 (PMID: 32301565) is the only record found that randomised dogs to both lokivetmab and oclacitinib; its reported comparisons are against the no-treatment control (oclacitinib significantly lower CADESI-03 in the first two weeks; lokivetmab prevented flares; hydration AUC higher for both drugs than controls), with no significant pruritus differences among any groups and no direct lokivetmab-versus-oclacitinib test — so the record does not rank the two drugs. (2) Independent appraisal: Cheung 2022 (PMID: 42007020), a Veterinary Evidence knowledge summary asking exactly whether lokivetmab is more effective than oclacitinib at reducing a recognised scoring-system score, critically appraised one randomised controlled trial (the Marsella study) and one before-and-after lokivetmab study; it states the randomised trial found both drugs similar in reducing the CADESI-03 score, grades the strength of evidence as weak, and concludes there is insufficient quality of evidence to answer the question and that further comparative study is required. (3) Neighbouring comparisons that home elsewhere and are NOT re-carded here: the blinded randomised trial of lokivetmab versus ciclosporin in 274 client-owned dogs (PMID: 28906040) is carded on Shelf #273, and the blinded randomised placebo-controlled trial of oclacitinib in client-owned dogs (PMID: 24581322) is carded on Shelf #270; neither compares lokivetmab with oclacitinib. (4) Design class (a): randomisation and blinding are established by the carded Marsella 2020 record for this shelf's own comparison and species; the MAYBE (weak evidence) stamp reflects that the evidence is a single 19-dog colony study over four weeks with no direct pairwise test between the two drugs.
Watch out: One-home check at drafting: PMID 32301565 and PMID 42007020 do not appear in any other pack on disk; PMIDs 28906040 and 24581322 are claim-carriers on Shelves #273 and #270 respectively and are cross-pointed here only. Do not read the synthesis as an equivalence finding: 'no direct test and no detected pruritus difference in 19 dogs' is absence of evidence, not evidence that lokivetmab and oclacitinib work equally well in pet dogs. If a client-owned head-to-head trial is published, this pack should be rebuilt.
Synthesis of Marsella R et al. PMID: 32301565; Cheung BYT. PMID: 42007020 (MeSH: none in the record); Moyaert H et al. PMID: 28906040 carded on Shelf #273; Cosgrove SB et al. PMID: 24581322 carded on Shelf #270. Registry IDs as on the individual records (none in the records).
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.